CERUS CORP (CERS) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Cerus Corporation develops and commercializes the INTERCEPT Blood System for pathogen reduction in platelets, plasma, and red blood cells. The company operates in one reportable segment and relies on product sales and government contracts (BARDA, DoD, FDA) for revenue. As of July 17, 2025, there were approximately 191.7 million shares of common stock outstanding.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $60,129 | $50,519 | $108,982 | $93,914 |
| Product Revenue | $52,445 | $45,079 | $95,684 | $83,444 |
| Government Contract Revenue | $7,684 | $5,440 | $13,298 | $10,470 |
| Gross Profit (Product) | $28,975 | $24,666 | $54,399 | $45,938 |
| Net Loss | $(5,715) | $(5,775) | $(13,433) | $(15,465) |
| Net Loss Per Share (Basic/Diluted) | $(0.03) | $(0.03) | $(0.07) | $(0.08) |
| Cash & Equivalents | $15,991 | $20,266 | $15,991 | $20,266 |
| Short-term Investments | $62,034 | $60,186 | $62,034 | $60,186 |
| Total Debt (Carrying Value) | $84,891 | $84,159 | $84,891 | $84,159 |
| Working Capital | $84,584 | $88,890 | $84,584 | $88,890 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 19% in Q2 2025 compared to Q2 2024. Product revenue grew 16% (driven by volume growth in Europe for Q2 and U.S. for YTD), while government contract revenue surged 41% (Q2) and 27% (YTD) due to the new 2024 BARDA Agreement.
- Profitability: Net loss narrowed slightly in Q2 2025 ($5.7M) compared to Q2 2024 ($5.8M). YTD net loss decreased to $13.4M from $15.5M in the prior year.
- Operating Expenses: R&D expenses increased 26% in Q2 and 21% YTD, primarily due to costs for a new LED-based illuminator, increased compensation, and BARDA-related work. SG&A expenses rose 12% in Q2 and 7% YTD, driven by compensation costs.
- Cash Flow: Net cash used in operating activities was $3.3M for the six months ended June 30, 2025, a reversal from the $2.4M provided in the same period in 2024. This shift was primarily due to increased inventory purchases and timing of collections/payments.
- Debt Structure: Total debt increased slightly to $84.9M. A reclassification of $8.1M of long-term debt to short-term occurred due to the amended Term Loan Credit Agreement.
Guidance, Outlook, and Risks
- Red Blood Cell System: The company is resubmitting its MDR application for the red blood cell system in the EU after a previous closure by the Dutch Medicines Evaluation Board (CBG). The company anticipates completing the RedeS clinical trial enrollment by the end of 2025 and trial completion in the second half of 2026. Additional clinical data may be required for FDA approval.
- Government Contracts: The 2024 BARDA Agreement provides potential funding up to $188.4M. The 2016 BARDA Agreement has $185.5M committed, with no further options expected to be exercised. Funding is contingent on meeting milestones and government budget availability.
- Supply Chain & Manufacturing: The company relies on Fresenius as the sole supplier for finished disposable kits. Delays in Fresenius qualifying new production facilities could impact growth. The company is transitioning to a new LED-based illuminator, which requires new PMAs in the U.S.
- Liquidity: Management believes cash, investments, and government contract funding will meet capital requirements for at least the next 12 months. However, the Term Loan begins amortizing in April 2026 unless restructured or extended.
- Regulatory Risks: Risks include potential delays in FDA approval for the red blood cell system, the need for new PMAs for the LED illuminator, and the impact of the "One Big Beautiful Bill Act" (OBBBA) enacted in July 2025 on tax law and Medicaid spending.
Investor Verification Checklist
- Red Blood Cell Regulatory Status: Verify the timeline and requirements for the resubmitted MDR application in the EU and the status of the RedeS clinical trial enrollment.
- Government Contract Funding: Monitor BARDA's exercise of option periods and the impact of U.S. federal budget decisions on the 2016 and 2024 agreements.
- Debt Amortization: Confirm plans regarding the Term Loan amortization starting April 2026 and the company's ability to service debt without restructuring.
- Inventory Levels: Assess the impact of rising inventory levels (current inventory increased to $54.5M) on future cash flow and potential obsolescence risks.
- LED Illuminator Approval: Track progress on obtaining new PMAs for the LED-based illuminator in the U.S. to ensure long-term product support.